This study is accepting new patients by invitation only

Precision Care for Major Depressive Disorder

a study on Depression

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Andrew D. Krystal, MD (ucsf)
Headshot of Andrew D. Krystal
Andrew D. Krystal

Description

Summary

This study aims to assess whether phenotyping-guided intervention selection is superior to intervention selection without phenotyping guidance (i.e., routine clinician and patient judgment regarding treatment selection) for depression.

Details

This study will classify patients seen in the Depression Clinic of the UCSF Department of Psychiatry and Behavioral Sciences into one of five phenotypes (subtypes), including: 1) Anhedonia, 2) Cognitive deficits, 3) Stress sensitivity, 4) Anxious distress, and 5) Grief.

After phenotyping, participants will be randomized to receive phenotype-specific intervention (PSI) or care as usual (CAU).

Keywords

Major Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Disorder, Pramipexole, Methylphenidate, Phenelzine, Dexpramipexole, Mindfulness-based Stress Sensitivity Therapy (MBSST), Complicated Grief Treatment (CGT), Anhedonia phenotype: PSI, Anhedonia phenotype: CAU, Cognitive deficits: PSI, Cognitive deficits: CAU, Stress sensitivity: PSI, Stress sensitivity: CAU, Anxious distress: PSI, Anxious distress: CAU, Grief: PSI, Grief: CAU

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participant is able to provide informed consent
  • English speaker
  • 18 years of age or older at time of consent
  • Meets DSM-5 criteria for Major Depressive Disorder
  • The subject meets eligibility criteria for at least one study phenotype as determined by assessments, imaging and/or clinical judgment.
  • PHQ-8 score at baseline of >= 10
  • Scheduled for or completed intake in UCSF outpatient psychiatry

You CAN'T join if...

  • Unstable or untreated medical or psychiatric condition based on clinical assessment by investigator(s)
  • Significant risk of suicidal or violent behavior as determined by clinical judgement
  • In the Investigators' opinion, the subject is not capable of adhering to the protocol requirements, or the subject has a history of poor or suspected poor compliance in clinical research studies, or the subject has a history of poor or suspected poor compliance to antidepressant medication or that study participation is not in their best interest (e.g., different treatment is indicated given their clinical presentation)
  • Pregnant or breastfeeding or planning to become pregnant during the study

Location

  • Nancy Friend Pritzker Psychiatry Building, University of California, San Francisco
    San Francisco California 94107 United States

Lead Scientist at University of California Health

  • Andrew D. Krystal, MD (ucsf)
    Dr. Krystal is the Ray and Dagmar Dolby Distinguished Professor in the Departments of Psychiatry and Neurology, Vice-Chair for Research in the Department of Psychiatry, Director of the Dolby Family Center for Mood Disorders, Director of the UCSF Interventional Psychiatry Program and Co-Director of the TMS & Neuromodulation Clinic.

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT06580041
Phase
Phase 4 Depression Research Study
Study Type
Interventional
Participants
Expecting 150 study participants
Last Updated